Merck & Co. (MRK) announced Sunday that preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab, its antibody therapy targeting PD-1, in patients with advanced melanoma, was presented at ASCO.
Merck & Co. gapped open higher Monday and is now up 1.90 at $48.60. The stock is challenging the highs of the year, trading at over a 1-month high.
For comments and feedback: editorial@rttnews.com